← All trials
NCT06549790
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 16, 2024
- Primary completion
- Sep 15, 2029
- Completion date
- May 15, 2030
- First posted
- Aug 12, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 124
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nerviano Medical SciencesLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.